Research programme: anti-cancer therapeutics - Delta-Fly Pharma

Drug Profile

Research programme: anti-cancer therapeutics - Delta-Fly Pharma

Alternative Names: DFP 14323; DFP 14927

Latest Information Update: 27 Jun 2016

Price : $50

At a glance

  • Originator Delta-Fly Pharma
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 27 Jun 2016 Early research in Solid tumours in Japan (PO) before June 2016
  • 27 Jun 2016 Preclinical trials in Solid tumours in Japan (IV) before June 2016
  • 27 Jun 2016 Delta-Fly Pharma plans a clinical trial for Pancreatic cancer and a phase II trial for Non-small cell lung cancer (In the elderly, Second-line therapy or greater) (Delta-Fly Pharma puipeline, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top